NCT01495195View on ClinicalTrials.gov

Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Cocaine Use Disorders
Interventions
DRUG

High-dose donepezil

Donepezil titrated to 22.5 mg daily

DRUG

Low-dose donepezil

Donepezil titrated to 10 mg daily

DRUG

Selegiline

Transdermal selegiline, 6 mg daily

DRUG

Placebo

microcrystalline cellulose

Trial Locations (1)

64128

Kansas City VA Medical Center, Kansas City

Sponsors
All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Midwest Biomedical Research Foundation

OTHER

NCT01495195 - Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior | Biotech Hunter | Biotech Hunter